drugset / Trial / NCT04129736
Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis
NaSingle-groupOpen-labelTreatment
Summary
Serum and cerebrospinal fluid will be obtained from 20 patients with relapsing-remitting multiple sclerosis treated with teriflunomide tablets 14 mg daily
Timeline
- Start
- 2019-10-10
- Primary completion
- 2021-03-31
- Completion
- 2021-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teriflunomide | Small molecule | 14 mg | — |
Indications
No indication recorded.